Valion Bio, Inc.
VBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787740
No open-market purchases or sales by Valion Bio, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $205.6K in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Valion Bio, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 7 | 9 | +2 |
| Shares | 81.9K | 264.2K | +182.3K (+222.5%) |
| Value | $118.8K | $233.4K | +$114.7K (+96.5%) |
New holders (5)
Institutions that held Valion Bio, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 87,818 | $77.8K | 0.00% |
| Sanctuary Advisors, LLC | 61,205 | $54.2K | 0.00% |
| HRT Financial LP | 42,419 | $37.0K | 0.00% |
| XTX Topco Ltd | 10,506 | $9.31K | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | $1 | 0.00% |
Sold out (3)
Institutions that held Valion Bio, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Susquehanna International Group, LLP | 14,639 | $21.2K |
| Citigroup Inc | 4,998 | $7.25K |
| Bank of America Corp | 13 | $19 |